Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post‐marketing surveillance

Hisashi Uhara, Yoshio Kiyohara, Taiki Isei, Kotaro Nagase, Anzu Kambe, Masashi Sato, Yutaro Tanaka, Naoya Yamazaki

Open source

DOI
10.1111/1346-8138.17096
Published
2024-03-03
Container
The Journal of Dermatology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/1346-8138.17096,
  title = {Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post‐marketing surveillance},
  author = {Hisashi Uhara and Yoshio Kiyohara and Taiki Isei and Kotaro Nagase and Anzu Kambe and Masashi Sato and Yutaro Tanaka and Naoya Yamazaki},
  year = {2024},
  journal = {The Journal of Dermatology},
  doi = {10.1111/1346-8138.17096},
  url = {https://doi.org/10.1111/1346-8138.17096}
}

RIS

TY  - JOUR
TI  - Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post‐marketing surveillance
AU  - Hisashi Uhara
AU  - Yoshio Kiyohara
AU  - Taiki Isei
AU  - Kotaro Nagase
AU  - Anzu Kambe
AU  - Masashi Sato
AU  - Yutaro Tanaka
AU  - Naoya Yamazaki
PY  - 2024
JO  - The Journal of Dermatology
DO  - 10.1111/1346-8138.17096
UR  - https://doi.org/10.1111/1346-8138.17096
ER  - 

APA

Uhara, H., Kiyohara, Y., Isei, T., Nagase, K., Kambe, A., Sato, M., Tanaka, Y., & Yamazaki, N. (2024). Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post‐marketing surveillance. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17096

Source records